Clinical trials

  • Talquetamab for Relapsed or Refractory Multiple Myeloma
  • TECLISTAMAB for Multiple myeloma
  • MIDOSTAURIN for Acute myeloid leukemia (AML) | Myelodysplastic syndrome with excess blasts-2 (MDS-EB2)
  • PATRITUMAB DERUXTECAN for Hormone receptor-positive (HR+) HER2-negative high-risk early breast cancer
  • MOGAMULIZUMAB for Cutaneous T-cell lymphoma | Mycosis fungoides | Sézary syndrome
  • DURVALUMAB for Non-small cell lung cancer
  • pembrolizumab for Thymic carcinoma|Nasopharyngeal cancer|Anal cancer|Head and neck squamous cell carcinoma|Epithelial ovarian cancer|Cutaneous melanoma|Mesothelioma|Non-small cell lung cancer|Esophagogastric cancer|Triple-negative breast cancer|Microsatellite instability-high colorectal cancer|Clear cell renal cell carcinoma
  • CENERIMOD for Systemic lupus erythematosus (moderate to severe)
  • GIVINOSTAT for Polycythaemia vera|JAK2V617F-positive polycythaemia vera|High-risk polycythaemia vera
  • INFLIXIMAB for Acute severe ulcerative colitis|Acute ulcerative colitis
  • VENETOCLAX for Chronic lymphocytic leukemia|Small lymphocytic lymphoma
  • LENZUMESTROCEL for Articular cartilage defect